Determination of the minimally important difference in WPAI
William J. Sandborn(University of San Diego), Laetitia Gerlier(UCB Pharma (Belgium)), Margaret C. Reilly, Yves Brabant, Martin C. Brown(Health Economics and Outcomes Research (United Kingdom)), Samuel Chin Wei Tan(Peking University)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
|New England Journal of Medicine|2012|794